A method for treating a subject suffering from cancer is provided. The method includes diagnosing the subject as suffering from cancer; obtaining Natural Killer (NK) white blood cells; upregulating the cathelicidin gene CAMP in the subject; and infusing the NK cells into the body of the subject.

A method for treating a subject suffering from cancer is provided. The method includes diagnosing the subject as suffering from cancer; obtaining Natural Killer (NK) white blood cells; upregulating the cathelicidin gene CAMP in the subject; and infusing the NK cells into the body of the subject.

The present invention relates to methods of treating a condition wherein NO has a beneficial effect, wherein such treatment comprises administering certain mono- and/or bis nitrosylated propanediols, including compositions and formulations thereof, wherein administration of said compounds, compositions or formulations is indirect to the pulmonary circulation and/or the systemic circulation of a patient in need thereof.

An applicator can include a dispenser for dispensing an amount of a therapeutic composition, which can include an amount of sugar or sugar alcohol and an amount of an alkalizing agent. In some cases, the alkalizing agent can include L-Arginine. In some cases, 75% or more of the composition by weight has a comedogenicity rating of 3 or less on a scale of 0-5. The dispenser can also have a power supply configured to provide power through a contact tip of the dispenser to provide nerve stimulation, such as using vibration, heating, cooling, and/or electrical stimulation.

An applicator can include a dispenser for dispensing an amount of a therapeutic composition, which can include an amount of sugar or sugar alcohol and an amount of an alkalizing agent. In some cases, the alkalizing agent can include L-Arginine. In some cases, 75% or more of the composition by weight has a comedogenicity rating of 3 or less on a scale of 0-5. The dispenser can also have a power supply configured to provide power through a contact tip of the dispenser to provide nerve stimulation, such as using vibration, heating, cooling, and/or electrical stimulation.

An applicator can include a dispenser for dispensing an amount of a therapeutic composition, which can include an amount of sugar or sugar alcohol and an amount of an alkalizing agent. In some cases, the alkalizing agent can include L-Arginine. In some cases, 75% or more of the composition by weight has a comedogenicity rating of 3 or less on a scale of 0-5. The dispenser can also have a power supply configured to provide power through a contact tip of the dispenser to provide nerve stimulation, such as using vibration, heating, cooling, and/or electrical stimulation.

An herbal combination composition can include, herbal extracts, including combinations of: Hyssopus officinalis, Zingiber officinale, Viola odorata, Ziziphus jujuba, Chamomile, and Ocimum tenuiflorum; pharmaceutical compositions, including combinations of: dextromethorphan, guaifenesin, acetaminophen, phenylephrine, diphenhydramine; polyethylene glycol; propylene glycol; poloxamer 407; ethylenediaminetetraacetic acid; methyl paraben; potassium sorbate; propyl paraben; xanthan gum; citric acid; anhydrous citric; and purified acetate buffered water. Also disclosed is a method for manufacture of an herbal combination composition, including dissolving herbal extracts, adding poloxamer, adding pharmaceutical compositions, adding acetate buffer, adding xanthan gum gel, adding acetate buffer.

An herbal combination composition can include, herbal extracts, including combinations of: Hyssopus officinalis, Zingiber officinale, Viola odorata, Ziziphus jujuba, Chamomile, and Ocimum tenuiflorum; pharmaceutical compositions, including combinations of: dextromethorphan, guaifenesin, acetaminophen, phenylephrine, diphenhydramine; polyethylene glycol; propylene glycol; poloxamer 407; ethylenediaminetetraacetic acid; methyl paraben; potassium sorbate; propyl paraben; xanthan gum; citric acid; anhydrous citric; and purified acetate buffered water. Also disclosed is a method for manufacture of an herbal combination composition, including dissolving herbal extracts, adding poloxamer, adding pharmaceutical compositions, adding acetate buffer, adding xanthan gum gel, adding acetate buffer.

The present disclosure relates to cannabinoid-based therapeutics, and their use in treating pain, e.g., chronic pain. The present disclosure also relates to cannabinoid-based therapeutics, and their use in treating opioid addiction.

The present disclosure relates to cannabinoid-based therapeutics, and their use in treating pain, e.g., chronic pain. The present disclosure also relates to cannabinoid-based therapeutics, and their use in treating opioid addiction.